Is grade 3 ductal carcinoma in situ considered breast cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Is Grade 3 DCIS Considered Breast Cancer?

Yes, ductal carcinoma in situ (DCIS) grade 3 is technically classified as breast cancer—specifically, stage 0 noninvasive breast cancer—but it is fundamentally different from invasive breast cancer in that it is nonlethal and confined within the breast ducts. 1

Understanding the Classification

DCIS represents a noninvasive stage of breast cancer where malignant epithelial cells remain confined within the ductal system by an intact basement membrane, without invasion into surrounding breast tissue 2, 3. The terminology can be confusing for patients because:

  • It is called "carcinoma" (cancer) because the cells have undergone malignant transformation with abnormal growth patterns
  • It is "in situ" meaning the cancer cells remain in their place of origin and have not invaded
  • It is stage 0 in the breast cancer staging system 1

Critical Distinction: Noninvasive vs. Invasive Disease

The most important concept to communicate is that DCIS is a nonlethal type of cancer because it stays in its normal place 2. This fundamentally distinguishes it from invasive breast cancer:

  • DCIS itself cannot metastasize or cause death
  • It is considered a nonobligate precursor to invasive breast cancer 4, 5
  • Only 40% of untreated DCIS lesions progress to invasive disease 4
  • Breast cancer-specific survival for DCIS is excellent 6

Grade 3 DCIS: Higher Risk Features

Grade 3 (poorly differentiated) DCIS does carry specific implications:

  • If progression occurs, grade 3 DCIS frequently gives rise to grade III invasive breast cancer 6
  • Grade 3 lesions demonstrate larger nuclear area, aneuploid DNA, and abundant vascular neogenesis, confirming more aggressive patterns than lower grades 7
  • These tumors show progressively increased microvessel density and proliferative markers compared to grades 1 and 2 7

Treatment Implications

Despite being noninvasive, DCIS requires treatment because:

  • The goal is preventing progression to invasive disease or detecting any invasive component early 1
  • Treatment options include breast-conserving surgery with or without radiation, or mastectomy 8
  • Local recurrence rates differ by treatment approach, but overall survival remains excellent regardless of surgical choice 8
  • If any invasive component is found on pathology review or re-excision, the patient must be treated according to invasive breast cancer guidelines 1

Common Pitfall to Avoid

Do not equate DCIS with invasive breast cancer when discussing prognosis and mortality risk. While DCIS is technically "breast cancer" by classification, patients need to understand that:

  • The prognosis is excellent with appropriate treatment
  • The disease is not immediately life-threatening
  • Treatment focuses on prevention rather than treating metastatic potential
  • The 1-2% relapse rate after mastectomy is due to unrecognized invasive foci, not the DCIS itself 8

In summary: Grade 3 DCIS is classified as stage 0 breast cancer, but it is a noninvasive precursor lesion with excellent prognosis when treated appropriately, fundamentally different from invasive breast cancer in terms of mortality risk.

References

Guideline

breast cancer: noninvasive and special situations.

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

Research

Ductal carcinoma in situ: terminology, classification, and natural history.

Journal of the National Cancer Institute. Monographs, 2010

Research

Advancements in Detection and Management of Ductal Carcinoma in Situ.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2025

Research

Update on Management of Ductal Carcinoma in Situ.

Clinical breast cancer, 2024

Research

Is DCIS breast cancer, and how do I treat it?

Current treatment options in oncology, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.